Summary We studied the growth characteristics and hypoxic fractions of DLD-2 human colon tumours xenografted into male nude mice either in the unperturbed state or after i.p. injection (q.i.d. x 7) of basic fibroblast growth factor (0.25 mg kg-') or suramin (50 mg kg-'). Hypoxic fractions were measured by clonogenic excision assay 1 day after administration b FGF or suramin was stopped. As compared to controls, the growth of tumours in b FGF treated mice was increased by a factor of 1.5 as indicated by the relative volumes of tumours on the day of excision. Similarly, suramin decreased the growth of DLD-2 tumours by a factor of 1.6. Moulder, 1990) , and the transients in hypoxic percentages seen during the postirradiation process of reoxygenation (Kallman & Dorie, 1986) . In addition, we have recently shown (Leith et al., 1991a) that the steady-state levels of hypoxia (about 10.5%) existing within unperturbed xenografted human A431 epidermoid carcinomas could be significantly altered by modification of the host growth factor status. Specifically, removal of the salivary glands in mice, which significantly reduces the circulating levels of epidermal growth factor (EGF), slowed volumetric tumour growth and concomitantly increased hypoxic fractions (to about 35%). Conversely, daily injections of EGF (0.25 mg kg-' day-1) in nonsialoadenectomised mice increased tumour growth and decreased hypoxic fractions (to about 3.5%). Therefore, systemic levels of growth factors that possess mitogenic and/or angiogenic properties (e.g., EGF) may be important in expression of intraneoplastic hypoxia. As improving tumour response and curability with ionising radiation is a major research focus, manipulation of intratumour hypoxia using growth factors is worthy of further study.
Moulder and Rockwell (1984) and Rockwell and Moulder (1990) have summarised the extent of hypoxia in various model tumour systems. In these reviews, the authors note that it is important to remember that quoted 'percentages' of hypoxia within tumours represent instantaneous steady-state values within dynamic systems. Examples of this dynamism are the increased hypoxic levels seen as tumour size increases (summarised in Rockwell & Moulder, 1990) , and the transients in hypoxic percentages seen during the postirradiation process of reoxygenation (Kallman & Dorie, 1986) . In addition, we have recently shown (Leith et al., 1991a ) that the steady-state levels of hypoxia (about 10.5%) existing within unperturbed xenografted human A431 epidermoid carcinomas could be significantly altered by modification of the host growth factor status. Specifically, removal of the salivary glands in mice, which significantly reduces the circulating levels of epidermal growth factor (EGF), slowed volumetric tumour growth and concomitantly increased hypoxic fractions (to about 35%). Conversely, daily injections of EGF (0.25 mg kg-' day-1) in nonsialoadenectomised mice increased tumour growth and decreased hypoxic fractions (to about 3.5%). Therefore, systemic levels of growth factors that possess mitogenic and/or angiogenic properties (e.g., EGF) may be important in expression of intraneoplastic hypoxia. As improving tumour response and curability with ionising radiation is a major research focus, manipulation of intratumour hypoxia using growth factors is worthy of further study.
To this end, we have investigated the DLD-2 xenografted human colon tumour system with respect to growth factor modulation of intratumour hypoxia by two additional treatments. First, we administered a different growth factorbasic fibroblast growth factor (b FGF), which has been reported to affect tumour growth (Gross et al., 1990) . Second, we administered an agent which blocks growth factor receptors, suramin, and which has been shown to inhibit the growth of xenografted human osteosarcomas (Walz et al., 1991) . The reasons for choosing the DLD-2 tumour model for these investigations were 2-fold. First, we have previously studied this tumour system in vivo, in regard to unperturbed volumetric growth and radiosensitivity (assayed by tumour growth delay) (Dexter et al., 1984 
Volumetric procedures
In this work, we followed the protocol used in our previous study of modification of hypoxic fractions in A431 xenografted tumours by EGF (Leith et al., 1991a) . Tumours were measured in two orthogonal diameters and volumes (mm3) were calculated using the formula for a prolate ellipsoid [V (mm3) = (L x W2)/2] where L and W are respectively the major and minor diameters (Leith et al., 1991a,b Determination of hypoxic fractions of xenografted DLD-2 tumours Tumours were irradiated in either air-breathing, unanaesthetised mice or mice that had been asphyxiated by a 10 min exposure to nitrogen gas prior to irradiation, as we have previously reported (Leith et al., 1991a,b) . For irradiations, mice were briefly anaesthetised with Metofane (methyoxyflurane; Pitman-Moore, Inc., Washington Crossing, NJ) and restrained on a lucite irradiation platform. Animals were allowed to fully recovery from the anaesthesia, and were then irradiated at room temperature using a Philips 250 kVp X-ray machine (Philips Ltd., Einthoven, the Netherlands), operated at 250 kV and 15 mA. Exposure doses were measured using a Victoreen R-meter (Victoreen Co., Cleveland, OH), and absorbed doses were calculated using appropriate temperature, pressure, and Roentgen to Gy conversion factors. The absorbed dose rate was about 1 Gy min-'.
For determination of clonogenic cell survival by excision assay, we delivered graded doses of 0-25 Gy to oxic and hypoxic tumours. In the b FGF or suramin treated mice, doses from 5-25 Gy were given. Immediately after irradiation, neoplasms were excised under sterile conditions, quartered, placed into ice-cold HBSS, and weighed. Then the pieces were minced using opposed scalpel blades into approximately 1 mm3 fragments, and placed into an enzyme cocktail containing 0.2% RNase The clonogenic X-ray survival curves for cells from control, b FGF, or suramin treated tumours are shown in Figure  2 . The dose-response curves for the cells from the various conditions (i.e., hypoxic, oxic, oxic plus b FGF or suramin) are parallel, fulfilling the necessary requirement for determination of hypoxic fractions (Moulder & Rockwell, 1984) . The b FGF and suramin administrations have clearly affected the hypoxic fractions (HFs) in the DLD-2 tumours as noted by the shifts in the position of the survival curves. Hypoxic fractions were calculated using the paired survival curve method for irradiated cells from tumours in air-breathing (SO) or in nitrogen gas asphyxiated mice (Sh) (Moulder & Rockwell, 1990) , in which the log of the HF is given by the vertical distance between the parallel curves at any given dose: log (HF) = log (S.)-log (Sh)
The geometric mean HFs and their 95% confidence limits were determined from the four estimates of HF obtained by comparing oxic and hypoxic survival at dose levels of 10, 15, 20 and 25 Gy. These values for the unperturbed, b FGF, and suramin conditions were respectively 0.422 (0.342-0.521), 0.191 (0.135-0.269), and 0.740 (0.653-0.839) . Therefore, b FGF treatment produces a stastically significant decrease in the hypoxic fractions of these DLD-2 neoplasms, while suramin produces a statistically significant increase.
Discussion
We have previously assayed the hypoxic fractions of 11 other xenografted human colon tumours at comparable sizes to the work reported herein on the DLD-2 tumour model (Leith et al., 1991b) . In the previous work, the geometric mean hypoxic percentage of the 11 tumours was 8.6% (95% confidence limits 2.8-25.9%), indicating that transplanted colorectal tumours as a class typically exhibit low steady-state levels of hypoxia. Only one tumour system (HCT-8) exhibited unusually high levels of intratumour hypoxia (about 82%). In this regard, the new data from analysis of the DLD-2 tumour system indicates a relatively high level of hypoxia in the unperturbed state (i.e., about 42%), which would alter the estimate of the geometric mean hypoxic percentage of colorectal tumours as a class to 9.8% (95% confidence limits 3.5-27.8%). The DLD-2 tumour appears to be an excellent model system. With steady-state hypoxic levels of 42%, changes in either direction produced by various treatments (e.g., EGF, b FGF, suramin) can be demonstrated with efficiency. Additionally, of all the excision assay studies that we have performed on different xenografted human colon tumours (Leith et al., 1991b) , the DLD-2 system exhibits the least variability in colony forming efficiency from both oxic The results obtained in this study with b FGF are consistent with our previous work on the effects of modulation of EGF status in the mouse on A431 tumour growth characteristics and hypoxic fractions (Leith et al., 1991a (Leith et al., 1991a) . Therefore, our previous results on modification of EGF levels (Leith et al., 1991a) A potential concern in the interpretation of the changes in hypoxic fractions seen with the b FGF or suramin treatments is that the hypoxic fractions were assayed in tumours of significantly different sizes (Figure 2 ). Because hypoxic fractions typically increase with increasing size (Rockwell & Moulder, 1990) , the influence of such an effect must be assessed for the studies reported herein. In this regard, it should be noted that even though the b FGF and suramin treated tumours are respectively larger and smaller than control neoplasms at the time of assay, they exhibit hypoxic fractions that are respectively smaller and larger than the hypoxic fraction seen in control tumours. That is, the change in intratumoural hypoxia levels are exactly opposite to what would be predicted solely on the basis of changes in tumour size.
Our results indicate an inverse relationship between tumour growth rate and levels of hypoxia. This would appear to be contrary to intuition. As stated Rockwell & Moulder (1990) , 'it might be predicted that slowly-growing tumours would have lower hypoxic fractions, because the vasculature would be better able to "keep up" with the growth of the tumour'. Whether our contrary experimental results are unique to this specific situation in which angiogenically active agents are involved requires further study. However, in other situations where tumours display slower growth than in the unperturbed state, as for example when tumours are implanted into a site that has received previous irradiation (Milas et al., 1989; Penhaligon et al., 1987; Leith, 1990) , increased hypoxic fractions are also found, consistent with the above results.
In summary, it is clear that descriptions of tumour growth and expression of intratumour hypoxia involve multiple aspects related to both the tumour and to the normal tissue. For example, with respect to considerations of parenchymal tumour cells, there are numerous publications that illustrate differential nature of growth factor expression or production, even for neoplasms within the same histological class (e.g., Anzano et al., 1989; Stefanik et al., 1991) . Host factors include organ-specific production of angiogenic polypeptides which would act systemically in a paracrine or endocrine fashion either on parenchymal tumour cells or on tumour stroma (e.g., EGF by salivary glands, various factors by regenerating liver) (Leith et al., 1991a; Fidler, 1991) . At the level of the local micro-environment, heparan sulfate proteoglycan is a major component of the extracellular matrix of some tumours, and is also a reservoir for b FGF (Folkman et al., 1988; Vlodavsky et al., 1991) . Additionally Esko et al. (1988) have shown that the in vivo growth of mutant tumour cells that produce relatively low levels of heparan sulfate proteoglycan is significantly reduced as compared to wild type tumour cells. Therefore, if the extracellular matrix varies (e.g., in the extent of heparan sulfate proteoglycan) from tumour to tumour, this might also be a covariate of both tumour growth and levels of intratumoural hypoxia. Further research into the explicit roles of tumour and host related factors is needed. This investigation was supported by Grant CA 50350 from the United States National Cancer Institute, DHHS.
